

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

CELLTRION, INC.,  
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,  
Patent Owner.

---

IPR2024-00260

U.S. Patent No. 11,253,572

**DECLARATION OF DR. CHRISTINE KAY**

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
II.	BACKGROUND AND QUALIFICATIONS .....	2
III.	INFORMATION RELIED UPON .....	5
IV.	RELEVANT LEGAL STANDARD .....	6
	A. Person of Ordinary Skill in the Art.....	7
	B. Claim Construction .....	9
	C. Presumption of Validity .....	10
	D. Obviousness.....	10
V.	TECHNOLOGY BACKGROUND.....	14
	A. Diabetic Retinopathy (DR) .....	14
	B. Diabetic Macular Edema.....	15
	C. Age-Related Macular Degeneration (AMD) .....	15
	D. VEGF Trap-Eye/Aflibercept.....	17
	E. Dosing Regimen for Intravitreal Injections of VEGF Antagonists .....	20
	F. Exclusion Criteria Intended to Reduce Risks Associated with Intravitreal Injections .....	22
VI.	BACKGROUND OF THE '572 PATENT.....	25
	A. General Description .....	25
	B. Prosecution History.....	27
VII.	CHALLENGED CLAIMS.....	28
VIII.	CLAIM CONSTRUCTION .....	29
	A. “A method for treating...” .....	29
	B. “Exclusion Criteria” .....	31
IX.	PRIORITY DATE .....	33
	A. Applicable Legal Standard.....	33

B.	Claim 25 of the '572 Patent Has an Earliest Effective Filing Date of July 12, 2013 at Best .....	35
X.	INVALIDITY UNDER 35 U.S.C. § 103 .....	37
A.	Overview of the Prior Art .....	37
1.	September 14, 2009 Press Release .....	37
2.	November 22, 2010 Press Release .....	38
3.	December 20, 2010 Press Release.....	39
4.	Dixon.....	40
5.	Hecht .....	41
6.	Shams 2006 .....	42
7.	Elman 2010.....	43
8.	CATT and PIER Studies .....	46
9.	Prior Art Regarding Efficacy of Aflibercept .....	50
B.	Analysis .....	52
1.	Claims 15 and 24 are Anticipated by Each of the 2009 Press Release and December 2010 Press Release.....	52
2.	Claims 1-5, 8-11, 16-17, and 20-21 (Generic/DME Results Claims) Are Anticipated by the December 2010 Press Release .....	55
3.	Claims 26-30 (AMD Results Claims) Are Anticipated by the November 2010 Press Release .....	60
4.	Claims 1-5, 8-11, and 26-30 (Generic/AMD Results Claims) Are Rendered Obvious by Dixon Alone or In View of the 2006 Press Release .....	64
5.	Claims 16-17, and 20-21 (DME Results Claims) Are Rendered Obvious by the 2009 Press Release Alone or in View of the 2007 ARVO Abstract, Dixon, and/or the 2010 ARVO Abstract (collectively, “Section X.B.5 References”) .....	72

6.	Claims 6-7 and 12-13 (Aflibercept Formulation) Are Rendered Obvious by Each of Dixon in View of Hecht, Dixon in View of the 2006 Press Release and Hecht, and the December 2010 Press Release in View of Hecht.....	76
7.	Claims 18-19 and 22-23 (Aflibercept Formulation) Are Rendered Obvious by Each of the December 2010 Press Release in View of Hecht, and the 2009 Press Release in View of the Section X.B.5 References and Hecht .....	78
8.	Claim 14 (Exclusion Criteria) Is Rendered Obvious by Each of Dixon, and the December 2010 Press Release Alone or In View of the CATT Study and/or PIER Study .....	78
9.	Claim 25 (Five Initial Doses) is Rendered Obvious by the 2009 Press Release Alone or in View of Shams or Elman 2010.....	81
10.	Claims 1-5, 8-11, and 26-30 (Generic/AMD Results Claims) are Anticipated by Dixon Because the “Results Limitations” Lack Patentable Weight.....	98
11.	Claims 1-5, 8-11, 16-17, and 20-21 (Generic/DME Results Claims) are Anticipated by the 2009 Press Release Because the “Results Limitations” Lack Patentable Weight.....	98
XI.	NO SECONDARY CONSIDERATIONS.....	99
XII.	SUPPLEMENTATION .....	100

## TABLE OF EXHIBITS

Exhibit	Description
1001	U.S. Patent No. 11,253,572
1003	Christine Kay <i>Curriculum Vitae</i>
1004	Institution Decision in <i>Apotex Inc. v. Regeneron Pharmaceuticals, Inc.</i> , IPR2022-01524. (“Apotex ’572 ID”)
1005	Press Release, “Enrollment Completed in Regeneron and Bayer Healthcare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) (September 14, 2009),” available at: <a href="https://newsroom.regeneron.com/news-releases/news-release-details/enrollment-completed-regeneron-and-bayer-healthcare-phase-3">https://newsroom.regeneron.com/news-releases/news-release-details/enrollment-completed-regeneron-and-bayer-healthcare-phase-3</a> (“2009 Press Release”)
1006	Press Release, “Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME),” Exhibit 99.1 to Regeneron 8-K filed on December 20, 2010, available at: <a href="https://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=7617341-6436-23571&amp;type=sect&amp;TabIndex=2&amp;companyid=5036&amp;ppu=%252fdef%E2%80%A6">https://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=7617341-6436-23571&amp;type=sect&amp;TabIndex=2&amp;companyid=5036&amp;ppu=%252fdef%E2%80%A6</a> (“December 2010 Press Release”)
1007	Press Release, “Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration,” Exhibit 99.1 to Regeneron 8-K filed on November 22, 2010, available at: <a href="https://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=7572010-8611-26486&amp;type=sect&amp;TabIndex=2&amp;companyid=5036&amp;ppu=%252fdef%E2%80%A6">https://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=7572010-8611-26486&amp;type=sect&amp;TabIndex=2&amp;companyid=5036&amp;ppu=%252fdef%E2%80%A6</a> (“November 2010 Press Release”)
1008	Apotex Petition for IPR filed in <i>Apotex Inc. v. Regeneron Pharmaceuticals, Inc.</i> , IPR2022-01524 (Paper 1) (“Apotex Petition”)
1009	Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. <i>Expert Opin Investig Drugs</i> . 2009;18(10):1573-1580. (“Dixon”)
1010	Major JC et al., “DA VINCI: DME and VEGF Trap-Eye: INvestigation of Clinical Impact: Phase 2 Study in Patients With Diabetic Macular

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.